摘要

新生兒糖尿病由於基因突變而使細胞無法正常釋放胰島素，症狀包括高血糖、多尿、糖尿病酮酸中毒等等。本案例為兩個月大女嬰，文獻建議口服sulfonylurea 首選為glibenclamide，但因面臨缺貨狀況，經由文獻查詢、院內sulfonylurea 品項比較及多方評估與討論後，選擇glimepiride 當作口服替代藥品。該案例定期回診追蹤，血糖狀況控制穩定且良好，藉由此一案例報告可提供新生兒糖尿病口服sulfonylurea 選擇之參考。

 

ABSTRACT

Neonatal diabetes mellitus is caused by gene mutations that impair normal insulin secretion. Symptoms include hyperglycemia, polyuria, and diabetic ketoacidosis. In this case, a two-month-old female infant was diagnosed with neonatal diabetes. Although glibenclamide is recommended in the literature as the first-choice oral sulfonylurea, it was unavailable due to a supply shortage. After reviewing relevant literature, comparing available sulfonylureas in the hospital, and conducting thorough evaluations and discussions, glimepiride was chosen as an oral alternative. The patient was regularly followed up, and her blood glucose levels remained stable and well-controlled. This case provides a reference for selecting oral sulfonylureas in the treatment of neonatal diabetes mellitus.

 

 

Submitted for publication: 2024.12.29; Accepted for publication: 2025.5.8